Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection by unknown
Zeng et al. Journal of Translational Medicine 2013, 11:6
http://www.translational-medicine.com/content/11/1/6RESEARCH Open AccessChemokine CXCL14 is associated with prognosis
in patients with colorectal carcinoma after
curative resection
Jun Zeng1†, Xudan Yang2†, Lin Cheng1†, Rui Liu1, Yunlong Lei1, Dandan Dong2, Fanghua Li2, Quek Choon Lau3,
Longfei Deng1, Edouard C Nice4, Ke Xie5* and Canhua Huang1*Abstract
Background: The chemokine CXCL14 has been reported to play an important role in the progression of many
malignancies such as breast cancer and papillary thyroid carcinoma, but the role of CXCL14 in colorectal carcinoma
(CRC) remains to be established. The purpose of this study was to investigate the expression pattern and
significance of CXCL14 in CRC progression.
Method: 265 colorectal carcinoma specimens and 129 matched adjacent normal colorectal mucosa specimens
were collected. Expression of CXCL14 in clinical samples was examined by immunostaining. The effect of CXCL14
on colorectal carcinoma cell proliferation was measured by MTT assay, BrdU incorporation assay and colony
formation assay. The impact of CXCL14 on migration and invasion of colorectal carcinoma cells was determined by
transwell assay and Matrigel invasion assay, respectively.
Results: CXCL14 expression was significantly up-regulated in tumor tissues compared with adjacent nontumorous
mucosa tissues (P < 0.001). Tumoral CXCL14 expression levels were significantly correlated with TNM (Tumor-node-
metastasis) stage, histodifferentiation, and tumor size. In multivariate Cox regression analysis, high CXCL14
expression in tumor specimens (n = 91) from stage I/II patients was associated with increased risk for disease
recurrence (risk ratio, 2.92; 95% CI, 1.15-7.40; P = 0.024). Elevated CXCL14 expression in tumor specimens (n = 135)
from stage III/IV patients correlated with worse overall survival (risk ratio, 3.087; 95% CI, 1.866-5.107; P < 0.001).
Functional studies demonstrated that enforced expression of CXCL14 in SW620 colorectal carcinoma cells resulted
in more aggressive phenotypes. In contrast, knockdown of CXCL14 expression could mitigate the proliferative,
migratory and invasive potential of HCT116 colorectal carcinoma cells.
Conclusion: Taken together, CXCL14 might be a potential novel prognostic factor to predict the disease recurrence
and overall survival and could be a potential target of postoperative adjuvant therapy in CRC patients.
Keywords: Colorectal carcinoma, CXCL14, Disease-free survival, Overall survival, PrognosisBackground
Colorectal carcinoma (CRC) is one of the most common
malignancies worldwide [1]. Over 1 million new cases of
colorectal carcinoma are diagnosed each year [2]. In
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reproduction in any medium, provided the ordeaths, with the incidence increasing annually [3]. Despite
improved radiotherapeutic and chemotherapeutic regi-
mens and surgical outcomes, almost half of the colorectal
carcinoma patients relapse within 5 years of treatment
and inevitably succumb to the disease. The prognosis and
treatment of colorectal carcinoma currently depends on
the pathologic stage of disease at the time of diagnosis and
primary surgical treatment. Unfortunately, disease stage
alone does not allow accurate prediction of outcome for
individual patients [4]. If patient outcomes are predicted
more accurately, treatments could be tailored to avoidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients who could be cured by surgery alone. Thus, new
biomarkers pivotal to tumor biology are urgently needed
to improve prognosis of the adjuvant treatment regimens.
Chemokines, a family of small (8–14 KDa) secreted pro-
teins that orchestrate leukocyte trafficking, have been impli-
cated in tumor development and progression [5-7]. They
exert their cellular effect by specifically activating corre-
sponding transmembrane G protein-coupled receptors [8].
Chemokines are classified into the C, CC, CXC, and CX3C
families, based on variations in a structural motif of con-
served N-terminal cysteine residues. Approximately 50 che-
mokines and 20 chemokine receptors have been identified.
Chemokines could promote the invasiveness of cancer cells
by triggering integrin clustering and enhancing their adher-
ence to extracellular matrix via their receptors [9,10]. Fur-
thermore, chemokines and chemokine receptors could also
serve as prognostic factors for cancer outcomes [11,12].
CXCL14 (originally identified as BRAK, BMAC, or Mip-
2γ) is a chemokine with as yet unknown function. This mol-
ecule was first identified by differential display using normal
epithelial cells and head and neck squamous carcinoma cells
and was shown to be expressed in many other normal tis-
sues and in various tumors of epithelial origin with hetero-
geneous expression levels [13-16]. As a unique member of
the chemokine family, the receptor for CXCL14 has not yet
been identified and the role of this molecule in tumor pro-
gression is controversial. Although the role of CXCL14 as a
tumor suppressor seemed well established, recent studies
suggested that CXCL14 might actually promote tumor pro-
gression [17,18]. For example, CXCL14 was reported to be
up-regulated in pancreatic cancer tissues compared to
chronic pancreatitis and normal pancreas [19]. It has also
been documented that CXCL14 transcript is markedly
higher in papillary thyroid carcinoma than in adjacent non-
cancerous tissues and positively correlated with lymph node
metastasis [20]. CXCL14 also acts as a multi-modal stimula-
tor of prostate and stomach tumor growth [15,21]. These
findings necessitate a re-evaluation of the function of
CXCL14 in epithelial tumors.
Till now, there has been little data suggesting the asso-
ciation between CXCL14 and colorectal carcinoma. This
study was therefore designed to investigate the expres-
sion and clinical significance of CXCL14 in colorectal
cancer. Our results showed that elevated CXCL14 ex-
pression in primary colorectal cancers was associated
with poor disease-free survival and overall survival, indi-
cating CXCL14 might be used as a potential prognostic
marker for CRC patients.
Materials and methods
Cell culture
HCT116, SW620, RKO and LoVo colorectal cancer cell
lines were purchased from American Type CultureCollection (ATCC, Rockville, MD). Cells were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM,
Invitrogen) containing 10% heat-inactivated fetal calf
serum (Hyclone, Logan, UT), penicillin (107 U/L) and
streptomycin (10 mg/L) at 37°C in a humidified chamber
containing 5% (v/v) CO2 in air.
Cloning of CXCL14, transfection and semi-quantitative RT-
PCR
To clone the CXCL14 cDNA, we isolated total RNA
from HCT116 cell line. First strand cDNA was reversely
transcribed from 1 μg of total RNA in a final volume of
20 μl using reverse transcriptase and random hexamers
with ExScript™ reagent kit (TaKaRa, Dalian, China)
according to the manufacturer’s instructions. Primers
were designed using Primer Premier 5 software. Primers
used were CXCL14: forward 50-CGG GAT CCA TGT
CCC TGC TCC CAC GCC-30, reverse 50-CCC TCG
AGC TAT TCT TCG TAG ACC CTG CGC TT-30
(336 bp product fragment). PCR was performed with
rTaq (TaKaRa) in a DNA thermal cycler (Bio-Rad)
according to a standard protocol as follows: initial de-
naturation (2 min at 94°C) followed by 30 cycles of de-
naturation at 94°C for 30 s, annealing at 56°C for 45 s,
and elongation at 72°C for 50 s. After the last cycle a ter-
minal elongation step (5 min at 72°C) was added and
thereafter the samples were kept at 4°C. PCR products
were run on 2.0% agarose gel, stained by SYBR Gold
(Molecular Probes, Eugene, OR), and analyzed under
UV light.
To construct a eukaryotic expression vector, the
CXCL14 cDNA was cloned into pcDNA3.1(+) plasmid
using the Eukaryotic TA Expression kit (Invitrogen Life
Technologies, Grand Island, NY) according to the man-
ufacturer’s instructions. Human colorectal cell line
SW620 was transfected with the human CXCL14 ex-
pression vector using Lipofectamine 2000 (Invitrogen
Life Technologies, Grand Island, NY) according to the
supplier’s instructions. Next, transfected cells were split
and treated with G418 (Invitrogen Life Technologies,
Grand Island, NY), and 12 clones were obtained. SW620
cells stably transfected with pcDNA3.1(+) empty vector
was used as mock control. Validation of the difference of
CXCL14 expression among colorectal cell lines was per-
formed by semi-quantitative RT-PCR. Gene transcrip-
tion of GAPDH and CXCL14 was analyzed by a two-
step reverse transcription-PCR as above.
Construction of and transfection with shRNA expressing
vector targeting CXCL14
A 21-mer shRNA expressing vector targeting CXCL14
(shCXCL14) and its scrambled sequence-expressing
vecotr as a negative control (shNC) were synthesized fol-
lowing the published literature [22]. The insert sequence
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TCA ACT GTG AAG CCA CAG ATG GGT TGA TGA
AGC GCT TGG TGC-30 and that for the scramble con-
trol shRNA was 50-GCC ATA CGC GAC ATA ACC
TCT GTG AAG CCA CAG ATG GGA GGT TAT GTC
GCG TAT GGC-30. The underlined nucleotides indi-
cated the 19-bp hairpin loop sequence. HCT116 cells
were transfected with those vectors by use of a Lipofec-
tamine. Cells treated with Lipofectamine alone were
used as a mock control. For proliferation and motility
assays, cells were transfected with those vectors for 24 h
before use. For expression analyses, cells were harvested
at 48 h post transfection.
Western blotting
Proteins were extracted in RIPA buffer (50 mM Tris-
base, 1.0 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Tri-
tonX-100, 1% Sodium deoxycholate, 1 mM phenyl-
methylsulfonyl fluoride) and quantified using the DC
protein assay kit (Bio-Rad, USA). Samples were sepa-
rated on 10% or 12% SDS-PAGE and transferred to
PVDF membranes (Amersham Biosciences). The mem-
branes were blocked overnight with PBS containing 0.1%
Tween 20 in 5% skimmed milk at 4°C and subsequently
probed using the following primary antibodies: rabbit-
anti-CXCL14 (diluted 1:400, Proteintech). Blots were
incubated with the respective primary antibodies for 2 h
at room temperature and washed 3 times in TBS with
Tween 20. Subsequently, the blots were incubated with
secondary antibodies (diluted 1:10,000; Santa Cruz Bio-
technology) conjugated to Horseradish Peroxidase for
2 h at room temperature. Target proteins were detected
by enhanced chemiluminescence reagents (Amersham
Biosciences, Piscataway, NJ), as previously described
[23]. β-actin was used as an internal control.
In vitro proliferation assays
5-Bromo-20-deoxyuridine (BrdU) incorporation assay,
was performed as previously described [24]. Cells were
seeded in 24-well culture plates at a density of 5 × 105,
grown to preconfluence (60%). After treatment, BrdU
(10 mM) (Roche Applied Science, Indianapolis, IN) was
added to each well and incubated for 4 h. Anti-BrdU
antibody (Zhongshan Biothechnology, Zhongshan, China),
appropriate fluorescein isothiocyanate-labeled second-
ary antibody were used. Staining was visualized using
confocal microscope (Leica, Heidelber, Germany). Cell
proliferation was determined by counting the number
of BrdU-positive cells in eight alternative areas. 3-(4,5-
methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT) assay was performed as described previously
[25]. For evaluation of cell growth in soft agar, cells
(3000 cells/well) were resuspended in DMEM contain-
ing 10% FBS with 0.35% agarose and layered on top of0.5% agarose in DMEM on 6-well plates. For colony
formation assay, SW620 cells (100 cells/well) were
resuspended in DMEM 10% FBS with rhCXCL14
(PeproTech) (0-100 ng/ml) on 6-well plates. Cultures
were maintained for 14 days and plates were stained
with Crystal Violet. Each experiment was done in
triplicate.
In vitro motility assays
Cell migration assays were performed in 24-well trans-
well chambers (Corning, NY). Cells in serum-free
medium (1 × 105 cells per well) were added to the upper
chamber. After 20 h, the number of cells that migrated
through the membrane to the lower chamber was
counted. For invasion assays, matrigel (1:3, BD) was
added to the transwell membrane chambers, incubated
for 4 h, and seeded with cells. Cells, which had migrated
to the lower chamber, were counted after 72 h, as previ-
ously described [26].
Surgical specimens
265 primary colorectal tumors and 129 corresponding
adjacent normal colorectal mucosa of the same subjects,
were collected from the patients who underwent surgical
resections during 2006 at the Sichuan Provincial People’s
Hospital (Chengdu, China). The primary tumors were
staged according to tumor-node-metastasis (TNM) clas-
sification system of the International Union against Can-
cer [27]. Tumor differentiation was graded according to
Edmondson Steiner grading by experienced pathologists.
Further clinicopathologic patient information was
extracted from the clinical notes and a summary of the
detailed colorectal cancer demographics is listed in
Table 1. Informed consent for tissue procurement was
obtained from all patients prior to analysis, and the pro-
ject was approved by the Institutional Ethics Committee
of Sichuan University.
Immunohistochemical staining
Tissues were formalin-fixed and paraffin-embedded, and
serial 4 μm thickness sections were taken for immunohis-
tochemistry analysis using a Dako Envision System (Dako
Cytomation GmbH, Hamburg, Germany Denmark)
according to the manufacturer’s instructions. Briefly, the
paraffin sections were deparaffinized, rehydrated, incu-
bated in 3% H2O2 for 10 min in the dark at room
temperature to block the endogenous peroxidase activity,
and antigen-retrieved in citrate buffer (pH 6.0) using auto-
clave sterilizer method. Subsequently, the sections were
preincubated with normal fetal calf or goat serum diluted
in PBS (pH 7.4) for 15 min at 37°C, followed by incubation
at 4°C overnight with the primary antibodies (rabbit anti-
CXCL14, dilution 1:50, Proteintech; rabbit anti-CXCL14,
dilution 1:200, Abcam; rabbit anti-Ki67, dilution 1:200,
Table 1 Colorectal cancer demographics
Characteristics Value


































Abbreviation: AJCC, American Joint Committee on Cancer.
*Ninety patients had paired adjacent normal colorectal mucosa specimens.
#Primary colorectal cancer tumors.
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with horseradish peroxidase-linked goat anti-rabbit anti-
bodies at 37°C for 40 min, followed by staining with 3,30-
diaminobenzidine (DAB) substrate solution (Dako Cyto-
mation GmbH) and counterstaining with Mayer’s
hematoxylin. Non-immune rabbit IgG at the same dilu-
tion as the primary antibody was used as the negative
controls.Evaluation of immunohistochemical staining
Cells with visible brown particles in the cytoplasm were
regarded as positive. All sections were evaluated by two
senior pathologists (Y.X. and D.D.), blinded to patient
outcomes and all clinicopathologic findings. The immu-
nohistochemical staining was evaluated based on the in-
tensity (weak = 1, intense = 2) of CXCL14 immunostaining
and the density (0% = inverse, 1-50% = 1, 51-75% = 2,
>76% = 3) of positive tumor cells [28]. The final scores of
each sample were multiplied intensity and density, and the
tumors were finally determined as inverse: score = 0; low
expression: score ≤ 3; high expression: score>3. If the eva-
luations did not agree the specimens were reevaluated and
then classified according to the assessment given most fre-
quently by the observers.
Statistical analysis
Analysis was performed with SPSS 16.0 for Windows
(SPSS Inc); qualitative variables were compared using
the Pearson χ2 Test and Fisher’s exact test; and quantita-
tive variables were analyzed by the t test. A Spearman
test for non-parametric variables was used to evaluate
correlation between clinical factors and CXCL14 expres-
sion. Survival curves for colorectal cancer patients with
high or low CXCL14 expression levels were constructed
using the Kaplan-Meier analysis. Univariate analysis of
clinical factors including age, sex, TNM stage, tumor in-
vasion, lymph node metastases, histodifferentiation, lo-
cation and tumor size was assessed by the log-rank test.
Multivariate analysis of disease-free survival and overall
survival were performed by the Cox proportional
hazards regression model using the forward stepwise
method when clinical prognostic factors were adjusted.
The results were considered statistically significant when
P value was less than 0.05.
Results
CXCL14 expression was up-regulated in CRC
To investigate the potential clinical role of chemokine
CXCL14 in colorectal cancer, immunohistochemistry
staining was performed on 265 colorectal cancer speci-
mens and 129 matched adjacent normal colorectal mu-
cosa specimens with an antibody to CXCL14, the
specificity of which we first confirmed (Additional file 1:
Figure S1A). Strong CXCL14 staining was mainly
observed in the cytoplasm of tumor cells, while partially
in the normal mucosa (Figure 1A). CXCL14-positive
staining was observed in 54.3% (70/129) of normal colo-
rectal mucosa samples, while in 85.3% (226/265) of pri-
mary CRC samples. CXCL14 expression was markedly
up-regulated in colorectal tumor tissues compared with
normal colorectal mucosa (P < 0.001, Figure 1B, C). Fur-
ther, high CXCL14 immunoreactivity was also found in
colorectal cancer tissues, compared to adjacent non-
Figure 1 A, CXCL14 expression was elevated in human colorectal cancer. Individual FFPE sections (e.g. case 1) demonstrated normal
colorectal mucosa, with adjacent colorectal cancer that had invaded underneath the normal mucosa. Inset in the left panel, the junction between
normal mucosa and adjacent tumor, shown at a higher magnification in the right panel, demonstrated the differences in the level of CXCL14
expression. ‘T’ refers to tumor tissue and ‘N’ refers to adjacent non-tumor tissue from the same patient. Bar, 100 μm. Paired samples of normal
colorectal tissue and colorectal tumor tissue from the same patients (e.g. case 2) demonstrated little detectable CXCL14 immunoreactivity in the
normal colorectal mucosa. In contrast, the colorectal tumor demonstrated intense CXCL14 immunostaining in the cytoplasm of the tumor. Bar,
50 μm. B, CXCL14 expression was plotted using the immunohistochemical scores in each carcinoma and adjacent normal tissues. C, CXCL14
expression scores were shown as box plots, with the horizontal lines representing the median; the bottom and top of the boxes representing the
25th and 75th percentiles, respectively; and the vertical bars representing the range of data.
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CXCL14, which may rule out the possibility of non-
specific staining (Additional file 1: Figure S1B). Most of
the stroma cells were CXCL14-negative, although spor-
adic positive staining on these cells was also observed.
These analyses suggested that up-regulation of CXCL14
might be involved in colorectal cancer initiation and
progression.
CXCL14 was correlated with several clinicopathologic
factors in CRC
We next analyzed the relevance between CXCL14 ex-
pression in tumor tissues and clinicopathologic factors.
The parameters included in this analysis were sex (male,
female), age (25–88 y), TNM stage (Stages I, II, III, IV),
tumor invasion (T1, T2, T3, T4), histodifferentiation
(well-, moderately and poorly differentiated), lymph
node metastasis (N0, N1, N2), tumor size (<2, 2–5, >5)
and location (colon, rectum). We found that the levels
of CXCL14 expression were positively associated with
TNM stage (P < 0.001, Figure 2A, C; Table 2), and re-
versely associated with histodifferentiation (P = 0.002,
Figure 2B, D; Table 2). Of the 226 CXCL14-positive
CRC cases, 8 were in Stage I (submucosa invasion), 83
in Stage II (subserosal invasion), 127 in Stage III (lymph
node metastasis) and 8 in Stage IV (distant metastasis);
and 57 were well-differentiated, 140 moderately and 29
poorly differentiated. In addition, the levels of CXCL14expression were positively correlated with tumor size
(P = 0.001, P = 0.003 for early-stage (I/II) colorectal car-
cinoma and late-stage (III/IV) colorectal carcinoma, re-
spectively, Table 3). No apparent correlation between
CXCL14 expression and other clinical factors was
observed (Table 3). These analyses indicated that up-
regulation of CXCL14 in colorectal cancer cells was cor-
related with tumor progression.
CXCL14 was correlated with disease recurrence
Patients with early-stage (I/II) colorectal carcinoma were
divided into low-CXCL14-expressing tumor group (n =
69) and high-CXCL14-expressing tumor group (n = 22).
Analysis by the Kaplan-Meier method revealed a signifi-
cant decrease in disease-free survival of high CXCL14-
expressing patients compared with low CXCL14-
expressing patients: 36.4% v 14.5% (Log-rank P = 0.018,
Figure 3A). By univariate analysis, CXCL14 expression,
number of lymph nodes, and tumor size were signifi-
cantly correlated with disease recurrence (Table 4). To
determine whether the prognostic value of CXCL14 ex-
pression was independent of other risk factors associated
with clinical outcome of colorectal carcinoma, multivari-
ate analysis was performed using Cox proportional haz-
ard model. The results showed only CXCL14 remained a
prognostic factor in disease-free survival of early-stage
colorectal carcinoma patients (risk ratio, 2.92; 95% CI,
1.15-7.40; P = 0.024; Table 4). Among all the AJCC stage
Figure 2 The level of CXCL14 expression was significantly correlated with TNM stage and histodifferentiation. A, strong
immunoreactivity was more likely to present with late-stage CRC compared to early-stage CRC (P < 0.001). Bar, 50 μm. B, poorly differentiated
colorectal tumors showed stronger immunoreactivity of CXCL14 than moderately and well differentiated colorectal tumors (P = 0.002). Bar, 25 μm.
C and D, comparison of immunohistochemical scores of CXCL14 according to TNM stage (C) and histodifferentiation (D).
Table 2 Relation between clinical factors and CXL14




Low High P value
TNM stage <0.001※
p I 7 (3.1%) 1 (0.4%)
p II 62 (27.4%) 21 (9.3%)
p III 66 (29.2%) 61 (27.0%)
p IV 2 (0.9%) 6 (2.7%)
Grade 0.002※
Well 41 (18.1%) 16 (7.1%)
Moderate 86 (38.1%) 54 (23.9%)
Poor 10 (4.4%) 19 (8.4%)
※ χ2 test.
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21 samples while expression of CXCL14 was relatively
low in other 62 samples. Those with tumors that highly
expressed CXCL14 also showed significantly poorer
disease-free survival (Log-rank P = 0.03, Figure 3B).CXCL14 was correlated with overall survival
The level of CXCL14 expression in primary colorectal
carcinoma specimens from 135 late-stage (III/IV) colo-
rectal carcinoma patients stratified these tumors as 67
high- and 68 low-CXCL14-expressing tumors. An over-
all survival analysis of 135 colorectal cancer patients
indicated that the level of CXCL14 expression was in-
versely correlated with survival time of the patients after
surgery. Patients with strong CXCL14 expression
showed significantly decreased overall survival. The
overall survival curves were constructed by the Kaplan-
Table 3 Comparison of clinical factors with CXCL14 for stage I/II patients and stage III/IV patients
Clinical Factors CXCL14 Expression (stage I/II) CXCL14 Expression (stage III/IV)
Low (n = 69) High (n = 22) P value Low (n = 68) High (n = 67) P value
Sex 0.599※ 0.543※
Female 27 (29.7%) 10 (11.0%) 34 (25.2%) 37 (27.4%)
Male 42 (46.2%) 12 (13.2%) 34 (25.2%) 30 (22.2%)
Age 0.878† 0.878†
Mean ± SD 62.4 ± 13.5 63.7 ± 14.1 58.7 ± 14.7 59.5 ± 14.0
Median 65 64 61 62
Range 25–88 35–82 25–84 29–88
TNM stage 0.674∮ 0.165∮
p I 7 (7.7%) 1 (1.1%)
p II 62 (68.1%) 21 (23.1%)
p III 66 (48.9%) 61 (45.2%)
p IV 2 (1.5%) 6 (4.4%)
Tumor invasion 0.123\ 0.522\
pT1 1 (1.1%) 0 (0%)
pT2 6 (6.6%) 1 (1.1%) 2 (1.5%) 2 (1.5%)
pT3 59 (64.8%) 18 (19.8%) 64 (47.4%) 61 (45.2%)
pT4 3 (3.3%) 3 (3.3%) 2 (1.5%) 4 (3.0%)
Lymph node No./metastasis 0.348\ 0.78\
0-7/pN0 20 (22.0%) 5 (5.5%) 2 (1.5%) 6 (4.4%)
8–12/pN1 37 (40.7%) 12 (13.2%) 56 (41.5%) 49 (36.3%)
>12/pN2 12 (13.2%) 5 (5.5%) 10 (7.4%) 12 (8.9%)
Grade 0.246\ 0.05\
Well 21 (23.1%) 7 (7.7%) 20 (14.8%) 9 (6.7%)
Moderate 42 (46.2%) 8 (8.8%) 44 (32.6%) 46 (34.1%)

















Table 3 Comparison of clinical factors with CXCL14 for stage I/II patients and stage III/IV patients (Continued)
Tumor size, cm 0.001\ 0.002\
<2 20 (22.0%) 0 (0%) 26 (19.3%) 11 (8.1%)
2-5 45 (49.5%) 18 (19.8) 34 (25.2%) 38 (28.1%)
>5 4 (4.4%) 4 (4.4%) 8 (5.9%) 18 (13.3%)
Location 0.100※ 0.191※
Colon 27 (29.7%) 13 (14.3%) 34 (25.2%) 41 (30.4%)
Rectum 42 (46.2%) 9 (9.9%) 34 (25.2%) 26 (19.3%)

















Figure 3 Cumulative disease-free and overall survival of CRC patients with high or low CXCL14 expression. A and B, Kaplan-Meier
disease-free survival curves to estimate survival of AJCC stage I/II CRC patients (A) and AJCC stage II CRC patients (B). C and D, Kaplan-Meier
overall survival curves to estimate survival of AJCC stage III/IV CRC patients (C) and AJCC stage III CRC patients (D). Comparison was made of
groups with high CXCL14 and low CXCL14 expression. Marks on graph lines represent censored samples. P value refers to two-sided log-rank
tests.
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rank P = 0.003, Figure 3C). To determine the prognostic
significance of CXCL14 as a predictor of overall survival
in patients with late-stage colorectal carcinoma, univari-
ate and multivariate analyses were conducted. By uni-
variate analysis, clinical factors including age, lymph
node metastasis and CXCL14 expression were signifi-
cantly correlated with overall survival (Table 4). Factors
that were significant in univariate analysis and showed a
trend toward significance were included in the multivari-
ate model. Results showed CXCL14 expression could be
used as a prognostic factor in overall survival of colorec-
tal carcinoma patients (risk ratio, 3.087; 95% CI, 1.866-
5.107; P < 0.001; Table 4). Patients with stage III CRC
were divided into low-CXCL14-expressing tumor group
(n = 66) and high-CXCL14-expressing tumor group (n =
61). By univariate analysis, CXCL14 expression (low ex-
pression v high expression) remained significantly differ-
ent for all stage III CRC patients (Log-rank P < 0.001,
Figure 3D).CXCL14 up-regulation was correlated with high
proliferation in CRC
To explore whether CXCL14 is correlated with the pro-
liferation of colorectal cancer cells, levels of Ki67, a mar-
ker of cell proliferation [29], were analyzed in 118
resected colorectal cancer specimens, which were also
examined with an antibody to CXCL14 (Figure 4A).
CXCL14 and Ki67 levels were plotted against each other,
and statistical analysis using the Spearman’s correlation
test showed significant correlation between these para-
meters (P < 0.01; Figure 4B). These results suggested that
CXCL14 might play a causal role in the induction of
proliferation in colorectal cancer.
Effect of CXCL14 on colorectal cancer cell proliferation
in vitro
To explore the effect of CXCL14 on colorectal cancer
cell proliferation, we investigated the expression levels of
CXCL14 mRNA and protein in four different colorectal
cancer cell lines: HCT116, SW620, RKO and LoVo
Table 4 Univariate and multivariate analyses of stage I/II disease-free survival and stage III/IV overall survival
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
Clinical Factors Recurrences/No. of Patients (stage I/II) Log-Rank P Risk Ratio (95% CI) Wald P Deaths/No. of Patients (stage III/IV) Log-Rank P Risk Ratio (95% CI) Wald P
Sex 0.314 1.0 NS 0.337 1.0 NS
Female 9/37 42/71
Male 9/54 43/64
Age, years 0.999 1.0 NS <0.001 3.753 <0.001
<70 13/65 58/99 (1.746-8.070)
≥70 5/26 27/36










Lymph node NO. /metastasis 0.006 1.0 NS <.001 4.450 <.001
0-7/pN0 9/25 2/8 (2.675-7.401)
8–12/pN1 4/48 65/105
>12/pN2 5/18 18/22
























Table 4 Univariate and multivariate analyses of stage I/II disease-free survival and stage III/IV overall survival (Continued)
Location 0.164 1.0 NS 0.440 1.0 NS
Colon 11/40 44/75
Rectum 7/51 41/60
CXCL14 0.018 2.92 (1.15-7.40) 0.024 0.003 3.087 (1.866-5.107) <0.001
Low 10/69 39/68
High 8/22 46/67

















Figure 4 Effects of CXCL14 expression on human colorectal cancer cell proliferation. A, immunohistochemical staining of human colorectal
tumor sections using CXCL14 and Ki67 antibodies. Bar, 25 μm. B, correlation between the expression levels of CXCL14 and Ki67 (n = 118; P < 0.01,
two-tailed Spearman test coefficient: 0.502). C, endogenous CXCL14 mRNA and protein levels were determined by semi-quantitative RT-PCR and
Western blotting in several colorectal cancer cell lines. D, CXCL14 was stably over-expressed in the SW620 subclones (clone 1 and clone 2). E-G,
proliferation of SW620 cells stably expressing CXCL14 or mock vector was compared by BrdU incorporation assay (E), MTT assay (F), and colony
formation assay (G), respectively. H, expression of CXCL14 in HCT116 cells was inhibited by transfection with shCXCL14. I-K, proliferation of
HCT116 cells transfected with shCXCL14 or shNC was measured by BrdU assay (I), MTT assay (J), and colony formation assay (K), respectively. Error
bars represent ± SD. Student’s t test was used for the statistical analyses. *, P < 0.05; **, P < 0.01.
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low levels of endogenous CXCL14 expression and thus
human CXCL14 cDNA was transfected into the cell line,
with G418 to allow the formation of colonies. Two
clones (clone 1 and clone 2) with elevated CXCL14 were
selected for further studies. Semi-quantitative RT-PCR
and Western blotting confirmed that CXCL14 was
stably over-expressed compared with mock control
(Figure 4D). MTT assay and BrdU incorporation assay
indicated that the two subclones grew significantly faster
than control cells (Figure 4E, F). We performed a colony
formation assay in 6-well plates. As expected, the results
showed that the two subclones yielded increased col-
onies compared with control cells (Figure 4G). In
addition, treatment with rhCXCL14 protein could pro-
mote SW620 cell proliferation (Additional file 2: Figure
S2A-C). While shRNA-mediated inhibition of CXCL14expression in HCT116 cells caused a significant decrease
in cell proliferation (Figure 4H-K). Collectively, these
data identified previously unrecognized growth-stimulatory
effects of CXCL14 on colorectal cancer cells.
Effect of CXCL14 on colorectal cancer cell motility in vitro
When analyzing the levels of CXCL14 expression in
colorectal carcinoma tissues by immunohistochemistry,
we found an interesting phenomenon that the number
of CXCL14-immunopositive carcinoma cells increased
as carcinoma cells invaded deeply and the tumor regions
that were more close to the invasion front showed stron-
ger CXCL14 immunoreactivity. Furthermore, the major-
ity of the cancer cells in the lymph node metastases
were also CXCL14-immunopositive (Figure 5A). These
phenomena suggested CXCL14 was involved in CRC in-
vasion and metastasis. Several in vitro studies were
Figure 5 CXCL14 promoted migration and invasion of SW620 cells. A, the deeply invading carcinoma cells were more intensely stained with
CXCL14 than those in mucosal region. ‘C muscle’ refers to circular muscle; ‘L muscle’ refers to longitudinal muscle. The cancer cells in the lymph
node metastases were also CXCL14-immunopositive. B-D, a 2-chamber assay was used for evaluation of the migration/invasion ability of SW620
subclones. Over-expression of CXCL14 significantly increased the migration and invasion abilities. The number of migrated (C) and invaded (D)
cells from five random fields were counted and presented with cell numbers. E-G, motility of HCT116 transfected with shCXCL14 or shNC were
compared by transwell assay (F) and Matrigel assay (G), respectively. Column, mean; bars, SE (from triplicates). Student’s t test was used for the
statistical analyses. *, P < 0.05; **, P < 0.01.
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clones (clone 1 and clone 2) migrated faster than control
cells through uncoated membranes in the modified Boy-
den chamber assays, and were more invasive than con-
trol cells as demonstrated by Martrigel invasion. The
numbers of migrated SW620 cells of CXCL14-transfeted
groups were 64 ± 7 and 56 ± 8 for clone 1 and clone 2,
respectively. Meanwhile the number of migrated cells in
mock vector-transfected cells was 20 ± 4. Further,
CXCL14 induced SW620 cell invasion by more than
threefold when compared with the control groups: 35 ±
5 (clone 1), 28 ± 6 (clone 2) versus 8 ± 2 (mock control)(Figure 5B-D). In addition, treatment with rhCXCL14
protein also accelerated SW620 cell migration and inva-
sion (Additional file 2: Figure S2D, E). However, shRNA-
mediated inhibition of CXCL14 expression in HCT116
cells caused a significant decrease in cell migration and
invasion (Figure 5E-G). These results demonstrated the
functional potential of CXCL14 in promoting colorectal
cancer cell migration and invasion.
Discussion
CXCL14, a novel non-ELR chemokine with yet unchar-
acterised receptor, has been reported to be associated
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study, we found that CXCL14 was frequently up-
regulated in colorectal tumors compared with the adja-
cent normal colorectal mucosa. This finding is consist-
ent with previous studies that CXCL14 expression was
elevated in tumor tissues compared with adjacent nor-
mal tissues [19,20,30]. To the best of our knowledge, this
is the first study that analyzes the expression of CXCL14
protein in colorectal carcinoma by immunohistochemis-
try using surgically resected neoplastic tissues. Further-
more, in early stage I colorectal cancer, CXCL14
expression was up-regulated compared with adjacent
normal mucosa, suggesting that CXCL14 over-expression
is an early event in the development of CRC. It is intri-
guing to speculate on possible reasons for these high
expression levels of CXCL14 during tumorigenesis.
Immunohistochemical analysis showed that CXCL14
expression was mainly located in malignant colorectal
epithelial cells, and partially in stroma cells. Hence, it
could be postulated that CXCL14, similar to other che-
mokines, is likely to signal through a G-coupled recep-
tor and contributes to progression of CRC via both
autocrine and paracrine pathways. Additionally, the
levels of CXCL14 expression were significantly asso-
ciated with some clinicopathologic factors including
TNM stage, histodifferentiation, and tumor size. Previ-
ous studies have reported that these factors are possible
predictors of early recurrence and cancer-death [31-33].
Among them, TNM stage is the strongest predictor of
survival for patients with colorectal cancer [32]. The
correlation between CXCL14 expression and these fac-
tors implies that elevated expression of CXCL14 may be
associated with poor patient outcome.
Multivariate analysis showed that elevated CXCL14
level in patients with stage I/II colorectal carcinoma was
an independent risk factor for developing recurrence,
and that the level of CXCL14 expression in patients with
stage III/IV colorectal carcinomas was inversely corre-
lated with duration of survival. CXCL14 is therefore a
useful prognostic factor for predicting the outcome of
patients with CRC who have had a surgical resection of
their tumor. Therefore, patients with colorectal carcin-
oma showing elevated CXCL14 expression should be
carefully followed-up, while those with no or low
CXCL14 expression should avoid being overtreated. In
addition, tumors with high CXCL14 expression had a
worse prognosis, even within the same clinicopathologic
stage. The staging system, which is based on the extent
of the tumor spread at the time of primary surgical
treatment, does not always account for the aggressive-
ness of the tumor itself. From a clinical perspective, the
ability to predict outcome within the same clinicopatho-
logic stage is the key to individualizing treatment
options. CXCL14, to some degree, helps makes up forthe fact that TNM stage per se cannot predict the out-
come of patients with the same clinical stage. Although
clinicopathologic data dealing with CXCL14 expression
at the protein level are currently scarce, increasing atten-
tion has been paid to the prognostic significance of
CXCL14 in other diseases. Using antibody arrays,
CXCL14 has been identified as a potential diagnostic
marker of hepatocellular carcinoma [34]. Additionally,
CXCL14 have been suggested to be a poor prognostic
marker in papillary thyroid carcinoma by qPCR analysis
[20].
The functional role(s) of CXCL14 in tumor biology
has been addressed in a few previous reports [15,17]. In
the present study, immunohistochemical analyses and a
number of in vitro studies were performed to validate
the aggressive role of CXCL14 in colorectal cancer pro-
gression. The observation that there was good correl-
ation between CXCL14 levels and Ki67 in human
colorectal cancer suggested that CXCL14 was involved
in human colorectal cancer cell proliferation. Indeed, we
found that CXCL14 enhanced malignant colorectal cell
proliferation in vitro. Consistent with these findings,
CAF-derived CXCL14 was reported to exert paracrine
stimulatory effects on the proliferation of the prostate
cancer cell line LNCaP [15]. Meanwhile, rhCXCL14 was
shown to enhance the proliferation of MCF-7 breast
cancer cell accompanied by a robust increase in ERK
phosphorylation in an autocrine manner [35]. Intri-
guingly, CXCL14 expression was observed to be
restricted to the myoepithelial cells in ductal carcinoma
in situ and the tumor epithelial cells in invasive breast
carcinoma, suggesting CXCL14 might be converted into
an autocrine factor from a paracrine factor [30].
In almost all the specimens studied, the deeply invaded
cancer cells were more intensely stained than those in
mucosal regions. Additionally, the number of CXCL14-
positive cancer cells increased as cancer cells invaded
deeply, with more than 90% of the cells in the regions of
the muscularis propria and subserosa immunopositive.
Furthermore, almost all the cancer cells in the lymph
node metastases were also CXCL14-immunopositive.
These results suggest CXCL14 may be involved in the
process of invasion and metastasis, especially lymphatic
permeation and nodal metastasis of colorectal cancer
cells. In vitro studies further validated the role of
CXCL14 in colorectal cancer cell migration and inva-
sion. The underlying mechanisms of CXCL14-enhanced
colorectal cancer cell migration and invasion are not
clear. Recent reports showed that activation of chemo-
kine signaling could promote tumor cell metastasis by
regulating polymerization of intracellular actins, indu-
cing formation of pseudopodia, and facilitating extracel-
lular matrix degradation and remodeling [36,37]. These
findings are consistent with previous studies that
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dicator of progression to tumorigenesis and metastasis
capacity [38,39]. However, few studies have reported the
potential of CXCL14 in colorectal carcinoma initiation
and progression. In contrast to previous studies in which
CXCL14 was reported to be deficient in tumors and
acted as a tumor suppressor [17,18], CXCL14 is recently
identified as a novel potential cancer-stimulatory protein
[20]. Results obtained from the present study together
with others indicate a need for further analysis of pos-
sible tumor type- and stage-specific effects of CXCL14
in other tumors [15,17,30]. The mechanisms through
which CXCL14 promotes or inhibits tumor progression
need to be further analyzed.
A series of topics worthy of further studies are sug-
gested by the present findings. Firstly, identification of
the receptor for CXCL14 is pressingly needed. The “seed
and soil” theory that target organs releasing specific che-
mokines attract tumor cells bearing corresponding
receptors has provided an acceptable explanation for
many important roles of chemokine receptors in cancer
metastasis [37,40]. Analyses of the effects of GPCR inhi-
bitors with known target profiles and GPCR profiling of
CXCL14-responsive and -nonresponsive cells, will pos-
sibly be useful for receptor identification. Identification
of the factor(s) that cause up-regulation of CXCL14 in
tumor epithelial cells is another relevant issue warrant-
ing further analyses. Understanding the mechanisms
through which the chemokine CXCL14 promotes cell
transformation and tumor progression is key to effective
therapy. We examined the expression pattern of
CXCL14 in CRC and its clinical value based on a small
number of cases. Thus, there is a requirement for fur-
ther investigations to clarify the correlation of CXCL14
expression with the clinical outcome of CRC with a lar-
ger patient cohort.Conclusion
In summary, these results provide the first definitive
immunohistochemical evidence that CXCL14 expression
is up-regulated in colorectal cancer. Additionally, we re-
port the potential clinical value of understanding
CXCL14 expression in patients with CRC. On the one
hand, CXCL14 could be used as a prognostic factor for
poor disease outcome. On the other hand, our studies
suggest that CXCL14 expression may be beneficial for
individualizing treatment options for CRC patients. One
of the challenges to effective therapy lies in understand-
ing the mechanisms through which the chemokine
CXCL14 promotes cell transformation and tumor pro-
gression. Understanding these mechanisms is essential
for developing new therapeutic strategies to effectively
inhibit cancer growth and metastasis. Taken together,our study can form the basis for future potential novel
tumor therapy.
Additional files
Additional file 1: Figure S1. The validation of the specificity of the
antibody to CXCL14. A, Immunohistochemical staining for colorectal
cancer specimens incubated with IgG or CXCL14-specific antibody. To
validate the specificity, the antibody (ProteinTech) to CXCL14 was pre-
incubated with recombinant human CXCL14 (PeproTech) for 1 h prior to
applying to tissues. B, some samples were randomly selected and
immunostaining experiments were done using both Proteintech’s and
Abcam’s anti-CXCL14 antibodies in serial sections.
Additional file 2: Figure S2. Effects of recombinant human CXCL14 on
colorectal cancer cell proliferation and motility. A-C, SW620 cells were
treated with rhCXCL14 at indicated doses. Proliferation of SW620 cells
were measured by BrdU assay (A), MTT assay (B), and colony formation
assay (C). D-E, rhCXCL14 significantly increased the cells’ migration and
invasion abilities. The number of migrated (D) and invaded (E) cells from
five random fields were counted and presented with cell numbers.
Column, mean; bars, SE (from triplicates). Student’s t test was used for the
statistical analyses. *, P < 0.05; **, P < 0.01.
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